Name: VERTEX PHARMACEUTICALS INC (VRTX) Stock
Brand: VERTEX PHARMACEUTICALS INC
Rating: 6.5 (3 reviews)

VRTX Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Chartmill - Mentions: ARE CRL BMY HUM ...

Which S&P500 stocks are moving on Wednesday?

3 days ago - By: Chartmill - Mentions: APA ARE CRL BMY ...

What's going on in today's session: S&P500 movers

14 hours ago - By: Zacks Investment Research - Mentions: ADMA

Adma Biologics (ADMA) Up 43.3% Since Last Earnings Report: Can It Continue?

a day ago - By: The Motley Fool

1 Reason I'll Never Sell Vertex Pharmaceuticals Stock

2 days ago - By: Zacks Investment Research - Mentions: TXN PG LRCX SD ...

Top Stock Reports for Procter & Gamble, Lam Research & Texas Instruments

3 days ago - By: Zacks Investment Research - Mentions: AMRN

Why Is Vertex (VRTX) Up 2.7% Since Last Earnings Report?

3 days ago - By: Zacks Investment Research - Mentions: MRNA CRSP

Vertex Up 9.2% in 3 Months: Should You Buy, Sell or Hold the Stock?

3 days ago - By: The Motley Fool - Mentions: GOOG

2 Brilliant Growth Stocks to Buy Now and Hold for the Long Term

5 days ago - By: Zacks Investment Research

Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock

16 days ago - By: Chartmill

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Presents a Compelling Case for Value Investors

16 days ago - By: Vertex Pharmaceuticals Incorporated

Vertex to Participate in the Citi’s 2025 Global Healthcare Conference on December 3

17 days ago - By: Benzinga

Here's How Much $100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth Today

18 days ago - By: Zacks Investment Research

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know

18 days ago - By: Benzinga

Is Vertex Pharmaceuticals Inc Gaining or Losing Market Support?

25 days ago - By: Zacks Investment Research - Mentions: ALKS CRMD CRSP

CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss Estimates

a month ago - By: Vertex Pharmaceuticals Incorporated

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week

a month ago - By: Zacks Investment Research

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know

a month ago - By: Zacks Investment Research - Mentions: ANIP NTLA CRSP

VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve?

a month ago - By: Zacks Investment Research - Mentions: ANIP NTLA CRSP

VERTEX PHARMACEUTICALS INC (VRTX) Stock News

VRTX Latest News, Press Relases and Analysis

Which S&P500 stocks are moving on Wednesday?

What's going on in today's session: S&P500 movers

Adma Biologics (ADMA) Up 43.3% Since Last Earnings Report: Can It Continue?

1 Reason I'll Never Sell Vertex Pharmaceuticals Stock

Top Stock Reports for Procter & Gamble, Lam Research & Texas Instruments

Why Is Vertex (VRTX) Up 2.7% Since Last Earnings Report?

Vertex Up 9.2% in 3 Months: Should You Buy, Sell or Hold the Stock?

2 Brilliant Growth Stocks to Buy Now and Hold for the Long Term

Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Presents a Compelling Case for Value Investors

Vertex to Participate in the Citi’s 2025 Global Healthcare Conference on December 3

Here's How Much $100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth Today

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know

Is Vertex Pharmaceuticals Inc Gaining or Losing Market Support?

CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss Estimates

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know

VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve?

Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint